ArticleCureus2026
Dedifferentiation of Metastatic Recurrent Chondrosarcoma of the Right Distal Femur Into High-Grade Sarcoma Favouring Leiomyosarcoma: A Report of a Rare Case With Review of Literature.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dedifferentiated chondrosarcoma (DDCS) is a rare and aggressive biphasic bone malignancy that accounts for a small but distinct proportion of all chondrosarcomas and primary malignant bone tumours. The high-grade dedifferentiated component most commonly resembles undifferentiated pleomorphic sarcoma or osteosarcoma. The prognosis is dismal, with low five-year overall survival rates that are further reduced in the presence of metastatic disease. Local recurrence occurs in a substantial proportion of patients even after wide-margin resection, and distant metastasis, most frequently to the lungs, is common. Systemic therapy offers limited benefit, with poor overall response rates and no durable remissions with currently available doxorubicin-based, ifosfamide-based, or targeted regimens. Leiomyosarcomatous dedifferentiation within DDCS is exceptionally rare, with only a handful of cases documented worldwide. We report a case in which a patient who underwent limb-salvage surgery for DDCS of the right distal femur in 2023 re-presented two years later with extensive metastatic local recurrence requiring palliative hip disarticulation. Immunohistochemical profiling of the resected specimen demonstrated a smooth muscle differentiation profile consistent with high-grade sarcoma favouring leiomyosarcoma arising within the dedifferentiated component, a finding with important implications for prognostication and systemic therapy selection. This case highlights the critical role of comprehensive tissue sampling, immunohistochemical subtyping, and multidisciplinary management in diagnostically complex bone sarcomas.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.